No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ACAD240517C23000
- 0.05
- -0.15-75.00%
15min DelayClose May 9 11:51 ET
0.05High0.05Low
0.05Open0.20Pre Close50 Volume93 Open Interest23.00Strike Price250.00Turnover146.08%IV51.55%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.0398Delta0.0255Gamma304.20Leverage Ratio-0.0160Theta0.0001Rho12.11Eff Leverage0.0020Vega
Intraday
- 5D
- 1D
News
ACADIA Pharmaceuticals | 10-Q: Quarterly report
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.
ACADIA Pharmaceuticals Price Target Cut to $27.00/Share From $33.00 by HC Wainwright & Co.
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
HC Wainwright & Co. : The ACADIA Pharmaceuticals (ACAD.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $27.00.
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
ACADIA Pharmaceuticals Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30
Citigroup analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $30.19 to $30.